首页> 外文OA文献 >Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-β-catenin signalling, the stem cell phenotype and disease progression
【2h】

Inflammatory breast cancer: Activation of the aryl hydrocarbon receptor and its target CYP1B1 correlates closely with Wnt5a/b-β-catenin signalling, the stem cell phenotype and disease progression

机译:炎症乳腺癌:芳基烃受体的激活及其靶CYP1B1与WNT5A / B-β-Catenin信号传导,干细胞表型和疾病进展紧密相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to evaluate the expression levels of the aryl hydrocarbon receptor (AHR) and its target gene CYP1B1 and to correlate their expression with Wnt5a/b-β-catenin, the CD44+/CD24(−/low) cancer stem cell (CSC) subset and factors associated with poor prognosis in inflammatory breast cancer (IBC) and non-IBC patients. The methods of analysis used were quantitative real-time PCR, western blotting, immunohistochemistry and flow cytometry. Compared to non-IBC tissues, IBC tissues exhibited the overexpression of AHR and its target gene/protein CYP1B1. AHR and CYP1B1 mRNA levels were associated with the poor clinical prognosis markers tumour grade, lymphovascular invasion, cell proliferation and lymph node metastasis. Furthermore, AHR expression correlated with the expression of Wnt5a/b and β-catenin signalling molecules, and Wnt5a mRNA expression was downregulated in the SUM149 human IBC cell line and the MDA-MB-231 non-IBC cell line upon inhibition of AHR. AHR gene knockout (CRISPR-Cas9) inhibits CYP1B1 and Wnt5a expression in the IBC cell line. The CD44+/CD24(−/low) subset was significantly correlated with the expression of AHR, CYP1B1, Wnt5a/b and β-catenin in IBC tissues. The overexpression of AHR and its target CYP1B1 correlated with the expression of Wnt5a/b and β-catenin, CSCs, and poor clinical prognostic factors of IBC. Thus, targeting AHR and/or its downstream target molecules CYP1B1 and Wnt5a/b may represent a therapeutic approach for IBC. Keywords: Inflammatory breast cancer, Aryl hydrocarbon receptor, CYP1B1, Wnt5a/b and β-catenin, CD44+/CD24(−/low) subset and lymphovascular invasion
机译:本研究的目的是评估芳香烃受体的表达水平(AHR)及其靶基因CYP1B1和它们与的Wnt5a / B-β连环蛋白的表达相关联,所述CD44 + / CD24( - /低)癌干细胞(CSC)子集与带有炎性乳腺癌(IBC)和非IBC患者预后不良相关的因素。使用的分析的方法是定量实时PCR,蛋白质印迹,免疫组织化学和流式细胞术。相对于非IBC组织,IBC组织表现出AHR的过表达和其靶基因/蛋白CYP1B1。 AHR和CYP1B1 mRNA水平与较差的临床预后标记物肿瘤分级,淋巴管浸润,细胞增殖和淋巴结转移相关联。此外,AHR表达的Wnt5a / B和β连环蛋白信号传导分子的表达相关,Wnt5a的mRNA表达在人类SUM149 IBC细胞系并且在抑制AHR的MDA-MB-231非IBC细胞系下调。 AHR基因敲除(CRISPR-Cas9)抑制CYP1B1和Wnt5a的表达在IBC细胞系。的CD44 + / CD24( - /低)子集显著与AHR,CYP1B1,Wnt5a的/ B和β-catenin在IBC组织中的表达相关。 AHR及其靶CYP1B1的过表达与的Wnt5a / B和β连环蛋白,的CSCs和IBC的不良临床预后因素的表达相关。因此,针对AHR和/或它的下游靶分子CYP1B1和Wnt5a的/ b可表示用于IBC的治疗方法。关键词:炎性乳腺癌,芳烃受体,CYP1B1,Wnt5a的/ B和β连环蛋白,CD44 + / CD24( - /低)子集,并且淋巴管浸润

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号